Journal of Medical Oncology and Therapeutics

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +441518081136

Commentary - Journal of Medical Oncology and Therapeutics (2024) Volume 9, Issue 4

Leukemia treatments and advances in targeted therapies and immunotherapy

Natacha Jordan*

Louvain Drug Research Institute (LDRI), UCLouvain, Université catholique de Louvain, Av. E. Mounier, 73 B1.73.08, 1200-Brussels, Belgium.

*Corresponding Author:
Natacha Jordan
Louvain Drug Research Institute (LDRI)
UCLouvain, Université catholique de Louvain
Av. E. Mounier, 73 B1.73.08, 1200-Brussels, Belgium.
E-mail: natacha@uclouvain.be

Received: 22-May-2024, Manuscript No.JMOT-24-139931; Editor assigned: 29-May-2024, PreQC No.JMOT-24-139931(PQ); Reviewed: 10-June-2024, QC No JMOT-24-139928; Revised: 16-June-2024, Manuscript No. JMOT-24-139931 (R); Published: 09-July-2024, DOI: 10.35841/jmot-9.4.218.

Citation: Jordan N. Leukemia treatments and advances in targeted therapies and immunotherapy. J Med Oncl Ther. 2024;9(4):218.

Visit for more related articles at Journal of Medical Oncology and Therapeutics

Introduction

Leukemia encompasses a variety of subtypes, broadly categorized into acute and chronic forms, each with distinct pathological features and clinical behaviors. Acute leukemias, including Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML), progress rapidly and require immediate intervention. In contrast, chronic leukemias, such as Chronic Lymphocytic Leukemia (CLL) and Chronic Myeloid Leukemia (CML), evolve more slowly and can sometimes be monitored for years before necessitating treatment  [1].

The heterogeneity of leukemia poses significant challenges in treatment. Each subtype responds differently to therapies, necessitating a tailored approach to care. This complexity has spurred the development of more precise and less toxic treatment modalities [2].

Targeted therapies have transformed the landscape of leukemia treatment by honing in on specific molecular abnormalities driving the cancer’s growth and survival. Unlike conventional chemotherapy, which indiscriminately attacks rapidly dividing cells, targeted therapies aim at cancer-specific pathways, reducing collateral damage to normal cells [3,4].

One of the most remarkable successes in targeted therapy is the use of Tyrosine Kinase Inhibitors (TKIs) in CML. The discovery of the BCR-ABL fusion gene, a product of the Philadelphia chromosome abnormality, paved the way for the development of imatinib (Gleevec), a TKI that specifically inhibits the BCR-ABL tyrosine kinase. This innovation has transformed CML from a fatal disease into a manageable chronic condition for many patients [5,6].

Another significant advancement is the introduction of BCL-2 inhibitors, such as venetoclax (Venclexta), which are used primarily in CLL and some subtypes of AML. BCL-2 is a protein that helps cancer cells evade apoptosis (programmed cell death). Venetoclax disrupts this process, allowing cancer cells to die naturally. When combined with other agents, venetoclax has demonstrated substantial efficacy in treating CLL, especially in patients who have relapsed or are refractory to other treatments [7].

CAR-T cell therapy represents a revolutionary approach in the treatment of certain leukemias, especially relapsed or refractory ALL and some forms of CLL. This therapy involves genetically modifying a patient's T cells to express chimeric antigen receptors (CARs) that can specifically target cancer cells. Once infused back into the patient, these CAR-T cells proliferate and attack the leukemia cells [8].

The future of leukemia treatment lies in the continued integration and refinement of targeted therapies and immunotherapy. Research is ongoing to identify new molecular targets and develop novel agents that can overcome resistance and minimize side effects. Additionally, combination therapies, which leverage the strengths of different treatment modalities, are being explored to enhance efficacy and reduce the likelihood of relapse [9].

Despite the progress, significant challenges remain, including managing treatment resistance, side effects, and the high costs associated with advanced therapies. Addressing these issues will be crucial to making these life-saving treatments accessible to a broader patient population [10].

Conclusion

The advancements in targeted therapies and immunotherapy are profoundly changing the prognosis for leukemia patients. While traditional treatments like chemotherapy remain important, these innovative approaches are providing new hope and improved outcomes for many. As research continues to uncover the underlying mechanisms of leukemia and develop more sophisticated therapies, the future holds promise for even more effective and personalized treatment strategies, bringing us closer to the goal of curing leukemia for all patients

References

  1. Lewis RE, Stanzani M. Antifungal prophylaxis in the era of targeted chemotherapy for acute myelogenous leukemia. Current Fungal Infection Reports. 2023;17(3):250-61.

    2. Indexed at, Google Scholar, Cross Ref

  2. Wu X, Wang F, Yang X, Gong Y, Niu T, Chu B, Qu Y, Qian Z. Advances in drug delivery systems for the treatment of acute myeloid leukemia. Small. 2024:2403409.

    3. Indexed at, Google Scholar, Cross Ref

  3. Kaito Y, Imai Y. Evolution of natural killer cell-targeted therapy for acute myeloid leukemia. International Journal of Hematology. 2024:1-0.

    4. Indexed at, Google Scholar, Cross Ref

  4. Rafei H, Kantarjian HM, Jabbour EJ. Recent advances in the treatment of acute lymphoblastic leukemia. Leukemia & lymphoma. 2019.

    5. Indexed at, , Google Scholar, Cross Ref

  5. Yip HY, Papa A. Signaling pathways in cancer: therapeutic targets, combinatorial treatments, and new developments. Cells. 2021 Mar 16;10(3):659.

    6. Indexed at, Google Scholar, Cross Ref

  6. Walasek A. The new perspectives of targeted therapy in acute myeloid leukemia. Adv Clin Exp Med. 2019;28(2):271-276.

    7. Indexed at, Google Scholar, Cross Ref

  7. Thomas X. Small Molecule Menin Inhibitors: Novel Therapeutic Agents Targeting Acute Myeloid Leukemia with KMT2A Rearrangement or NPM1 Mutation. Oncology and Therapy. 2024;12(1):57-72.

    8. Indexed at, Google Scholar, Cross Ref

  8. Papadantonakis N, Advani AS. Recent advances and novel treatment paradigms in acute lymphocytic leukemia. Ther Adv Hematol 2016; 7(5): 252-269.

    9. Indexed at, Google Scholar, Cross Ref

  9. Bazinet A, Kadia TM. Changing paradigms in the treatment of acute myeloid leukemia in older patients. Clinical Advances in Hematology & Oncology: H&O. 2022;20(1):37-46.

    10. Indexed at, Google Scholar

  10. Talekar MK, Grupp SA. Chimeric Antigen Receptor T Cells for Leukemias in Children: Methods, Data, and Challenges. Cell and Gene Therapies. 2019:55-73.

    11. Indexed at, Google Scholar, Cross Ref

Get the App